PHVS:NASDAQPharvaris N.V. Analysis

Pharvaris N.V. (PHVS) is trading at $28.63, comfortably above its 20‑day SMA of $28.28 and the 50‑day SMA of $27.39, indicating a short‑term bullish bias. The price sits near the mid‑point of its 52‑week range, with a clear support level at $26 and resistance at $30.24, while the RSI of 53 suggests neither overbought nor oversold conditions. Although the MACD histogram is marginally negative, the overall trend remains bullish and the “Extreme Greed” sentiment (Fear & Greed Index 88) supports continued buying pressure. Volatility is elevated at roughly 51% over the past 30 days, and beta hovers around 1.0, reflecting market‑aligned risk. Fundamentally, the company reports zero revenue and negative earnings, but it holds $291.7 M in cash against minimal debt ($0.78 M), yielding a high price‑to‑book multiple of 5.86. Analyst consensus is strongly positive, with a “strong_buy” rating, 13 analysts, and a mean target price of $46.83, implying a potential upside of over 60%. Recent Wolfe Research coverage initiating an “Outperform” stance adds further credibility to the upside thesis. The pipeline’s phase‑3 deucrictibant program targets rare, high‑unmet‑need diseases, which could catalyze future revenue once approved. Despite the cash‑burn and lack of profitability, the robust cash runway and low leverage mitigate immediate financial distress. In summary, PHVS presents a high‑growth, high‑risk profile where technical strength, analyst support, and a promising clinical program align to justify a bullish outlook.